Does Birth Control Cause Weight Gain With PCOS? What the Trials Show

Does the birth control pill actually cause weight gain with PCOS?

A 2025 randomized trial of 240 women with PCOS found the opposite of what most people expect walking in. The COMET-PCOS trial randomized women aged 18 to 40, all with hyperandrogenic PCOS and a BMI between 25 and 48 kg/m², to 24 weeks of a low-dose combined pill (20 mcg ethinylestradiol / 0.15 mg desogestrel), metformin, or both. In the combined-pill group, BMI fell by a mean of 0.49 kg/m² (95% CI −0.88 to −0.10, p = 0.01), waist circumference dropped 2.23 cm, and android fat mass on DXA scan fell by 167 g — while the metformin-only group showed no significant change in any of those three measures. The trial’s own authors wrote that this “challenges the current practice” of assuming metformin protects against weight gain that the pill supposedly causes.

That is one trial, run for 24 weeks, with a moderate sample size — not proof the pill helps every person lose weight, and not the last word on year three or year five. But it directly contradicts the assumption most people bring to this question, and it did so in the population this article is for: women with PCOS who also carry excess weight.

Then why do so many people say they gained weight on the pill?

Two real mechanisms, plus one coincidence of timing, explain the mismatch between trial averages and individual reports — and none of it means what you are noticing in the mirror or on the scale is imagined.

Fluid retention is real and separate from fat gain. Estrogen stimulates the liver to produce more angiotensinogen, which raises circulating aldosterone and drives the kidneys to hold onto sodium and water. A progestin with no counteracting effect on that pathway leaves the fluid retention unopposed; drospirenone, by contrast, has genuine antimineralocorticoid activity and was specifically developed to counteract that estrogen-driven sodium retention. Water retention shows up on a scale exactly like fat does, but it moves faster, fluctuates with cycle phase and salt intake, and is not the same physiological change as gaining body fat. If it is PCOS itself, rather than contraception, that you suspect is behind the number on the scale, the four mechanisms behind PCOS weight gain — insulin, androgens, appetite hormones and energy expenditure — is the separate question that article answers.

Trial averages can hide individual variation. A mean difference near zero across 2,000 women does not mean every one of those 2,000 women stayed exactly the same weight — it means the people who gained and the people who lost roughly balanced out. Your result being on one side of that average is not a contradiction of the data; it is what an average is made of.

Timing gets misread as causation. Hormonal contraception often starts at moments — after puberty, after a pregnancy, during a stressful stretch, alongside a different life stage — when weight was already likely to shift for reasons that have nothing to do with the prescription. The pill is simply the most recent variable to point to.

Does the type of pill change the weight picture?

A 2023 review of 19 randomized trials found that the pill formulation itself changes the weight picture somewhat — more specific than treating “the pill” as one category. The review, built specifically to update the international PCOS guideline, pooled trials comparing different combined pills against each other in women with PCOS and found that fourth-generation pills produced a lower BMI than third-generation pills, by a mean difference of 1.17 kg/m² (95% CI 0.33–2.02), and that pills combining ethinylestradiol with cyproterone acetate outperformed “conventional” combined pills on both BMI (mean difference 0.62 kg/m², 95% CI 0.05–1.20) and testosterone reduction.

That EE/cyproterone-acetate result is a real trade-off, not a free upgrade: the same review notes it carries a higher venous thromboembolism risk in the general population and is not recommended as a first-line choice for that reason, whatever its BMI and androgen advantage looks like on paper. Which progestin is right for a given prescription is a conversation for your prescriber, weighing all of it together — not a swap to request based on one line of one table.

Is the birth control injection different from the pill?

Yes: a 2016 Cochrane review of 22 studies and 11,450 women, covering the injection, implants, hormonal IUDs and progestin-only pills, found the injection is the one method where “birth control” as a single category genuinely breaks down. Most comparisons in that review showed no significant weight difference. The injection was the exception. One retrospective study found women using the injection gained 2.28 kg more than copper IUD users in year one, 2.71 kg more in year two, and 3.17 kg more in year three. A separate retrospective study found a similar widening gap at years one, four and ten.

A large randomized trial confirms the pattern with better methodology. The ECHO trial randomized 7,014 women across four African countries to the injection, a levonorgestrel implant, or a copper IUD and measured weight at 12 to 18 months. Mean gain was 3.5 kg on the injection, 2.4 kg on the implant, and 1.5 kg on the copper IUD — a 2.02 kg difference between the injection and the IUD (95% CI 1.68–2.36, p < 0.001) that held up under randomization, not just observation.

Baseline weight status changes how large that effect gets. In a study of 450 adolescent girls, those who were already obese and started the injection gained a mean 9.4 kg over 18 months, versus 0.2 kg on the combined pill and 3.1 kg with no hormonal method. Nonobese adolescents on the injection gained less — 4.0 kg, against 2.8 kg on the pill and 3.5 kg with no method — meaning the injection’s effect size was roughly twice as large in girls who started at a higher weight.

Does this mean the combined pill is the obvious choice?

Not automatically: the 2023 international guideline names the combined pill first-line pharmacological treatment for menstrual irregularity and hyperandrogenism in PCOS, and that recommendation exists independent of the weight question, built on its effects on bleeding pattern and circulating androgens. What actually counts as irregular cycles in PCOS is its own guideline definition, separate from weight, and worth knowing before you weigh that trade-off. If weight concern is the only reason you are considering stopping a pill that is otherwise managing your cycles or hirsutism well, the trial evidence in this article does not support that specific reason on its own. Birth control for PCOS covers what the pill actually treats, what it masks for diagnosis, and how progestin choice affects hirsutism and clot risk in more depth than belongs here.

Who does the “trials don’t show it” reassurance not apply to?

Three groups should read the evidence above differently, not more anxiously, but more specifically.

• Anyone on the progestin-only injection, especially if you started it at a higher body weight. The randomized evidence for a real, measurable weight gain is strongest here, not weakest. This is not a case where “the studies don’t show it” applies — the studies do show it.
• Anyone whose main complaint is visible bloating or puffiness, particularly in the first one to three cycles. That pattern fits fluid retention far better than fat gain, and it is worth naming to a prescriber as a fluid symptom specifically, since some progestins address it and others do not.
• Anyone weighing a formulation switch on cyproterone acetate’s BMI advantage alone. That comparison came with a higher clotting risk attached in the same body of evidence, which is a reason to discuss it, not a reason to request it outright.

What to actually bring to that conversation

Three questions turn this evidence into something useful at your next appointment. First, ask which progestin is in your current or proposed pill, and whether it has antimineralocorticoid activity, if fluid-related weight change is your main concern — that is a specific, answerable question, not a vague one. Second, if you are on the injection and weight change is bothering you, say so plainly and ask what the comparative evidence looks like for the methods available to you; this is a case where the evidence genuinely differs by method, not one where you need convincing that your experience is real. Third, if you want to separate water weight from fat change, track weight under consistent conditions — same scale, similar time of day, same rough point in your cycle — over several months rather than day to day, since fluid retention swings with sodium intake and cycle timing in ways that fat mass does not. If contraception turns out not to be the driver and you want the fuller picture of what actually moves weight in PCOS, the full PCOS weight-loss guide in the weight-loss section covers diet, exercise, metformin and GLP-1 evidence with realistic timelines attached.

You may see PCOS referred to as polyendocrine metabolic ovarian syndrome (PMOS) after a 2026 global consensus of more than 50 organizations renamed it — same condition, same mechanism, only the label changed. This article uses PCOS because that is still what most people search.